Max Health is pleased to announce a resolution to the recent issues with Prochlorperazine 3mg buccal tablets. Max Health Director David Pascoe, said, “in order to address the needs of the New Zealand market, we have partnered with UK company Brown and Burk to achieve Medsafe registration of Prochlorperazine 3mg buccal tablets and ongoing supply for our local market.”
Prochlorperazine is indicated for a variety of conditions including:
-
the symptomatic treatment of vertigo due to Meniere’s Disease, Labyrinthitis and other causes
-
nausea and vomiting from whatever cause and
-
in the treatment of migraine1.
Max Health’s prochlorperazine 3mg buccal tablets are now:
-
Medsafe registered and
-
listed on the pharmaceutical schedule*.
*A part-charge will apply
1. Prochlorperazine data sheet, December 2024, www.medsafe.govt.nz
Prochlorperazine maleate 3mg buccal tablets.
Indications: Prochlorperazine maleate is indicated in adults & children >12 yrs: Symptomatic treatment of vertigo due to Meniere’s Disease, Labyrinthitis and other causes; For nausea and vomiting from whatever cause; In the treatment of migraine.
Warnings & Precautions: Use with caution in patients with stroke risk factors; myasthenia gravis; AIDS; hypotension; dementia; neuroleptic malignant syndrome; venous thromboembolism; QT prolongation & carbohydrate malabsorption disorders.
Interactions: Alcohol, CNS depressants; antihypertensives; neuroleptics; anticoagulants; Anticonvulsants; lithium; desferrioxamine; levodopa; anti-arrhythmics, antidepressants, macrolide-antibiotics & other antipsychotics.
Prochlorperazine maleate is a partially funded prescription only medicine. Please review the full Data Sheet before prescribing. Data sheets are available at www.medsafe.govt.nz .
Distributed by Max Health Ltd, Auckland. Date of Preparation March 2025. MXH/NZ/PROCHLORPERAZINE/002.
